Clinical Trial | NCT Number | Sponsor | Condition | Start Date | Phase |
---|
NCT05412004 | Eli Lilly and Company | Sleep Apnea|Obesity | June 21, 2022 | Phase 3 | NCT03940742 | Eli Lilly and Company | Hepatic Insufficiency | July 22, 2019 | Phase 1 | NCT04844918 | Eli Lilly and Company | Obesity | May 10, 2021 | Phase 3 | NCT03882970 | Eli Lilly and Company | Type 2 Diabetes Mellitus | April 1, 2019 | Phase 3 | NCT05708859 | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center|Eli Lilly and Company | Type II Diabetes|Atherosclerosis | August 2023 | Phase 4 | NCT04657016 | Eli Lilly and Company | Obesity|Overweight | March 29, 2021 | Phase 3 | NCT03311724 | Eli Lilly and Company | Type 2 Diabetes | October 19, 2017 | Phase 2 | NCT05822830 | Eli Lilly and Company | Obesity|Overweight | April 21, 2023 | Phase 3 | NCT04407234 | Eli Lilly and Company | Overweight|Obesity|Diabetes Mellitus, Type 2 | September 15, 2020 | Phase 1 | NCT04184622 | Eli Lilly and Company | Overweight|Obesity | December 4, 2019 | Phase 3 | NCT03730662 | Eli Lilly and Company | Type 2 Diabetes Mellitus | November 20, 2018 | Phase 3 | NCT03322631 | Eli Lilly and Company | Type 2 Diabetes Mellitus | November 15, 2017 | Phase 1 | NCT05564039 | Eli Lilly and Company | Type 2 Diabetes | November 30, 2022 | Phase 4 | NCT04004988 | Eli Lilly and Company | Healthy | August 19, 2019 | Phase 1 | NCT05260021 | Eli Lilly and Company | Type2 Diabetes|Diabetes Mellitus|Diabetes Mellitus, Type 2|T2D|T2DM (Type 2 Diabetes Mellitus)|Glucose Metabolism Disorders|Endocrine System Diseases|Metabolic Disease | April 13, 2022 | Phase 3 | NCT03375463 | Eli Lilly and Company | Healthy | December 19, 2017 | Phase 1 | NCT04537923 | Eli Lilly and Company | Type 2 Diabetes | October 19, 2020 | Phase 3 | NCT05536804 | Eli Lilly and Company | Overweight|Obesity|Chronic Kidney Disease|Type 2 Diabetes|T2D | February 8, 2023 | Phase 2 | NCT03861052 | Eli Lilly and Company | Type 2 Diabetes | May 7, 2019 | Phase 3 | NCT03482024 | Eli Lilly and Company | Renal Insufficiency|End Stage Renal Disease | March 30, 2018 | Phase 1 | NCT04093752 | Eli Lilly and Company | Type 2 Diabetes | December 9, 2019 | Phase 3 | NCT04166773 | Eli Lilly and Company | Nonalcoholic Steatohepatitis | November 19, 2019 | Phase 2 | NCT04172987 | Eli Lilly and Company | Healthy | February 26, 2020 | Phase 1 | NCT03954834 | Eli Lilly and Company | Type 2 Diabetes Mellitus | June 3, 2019 | Phase 3 | NCT05963022 | Eli Lilly and Company | Type 2 Diabetes | September 5, 2023 | Phase 3 | NCT05553093 | Nanjing First Hospital, Nanjing Medical University | Type 2 Diabetes Mellitus | March 15, 2022 | Phase 4 | NCT04039503 | Eli Lilly and Company | Type 2 Diabetes | August 30, 2019 | Phase 3 | NCT05810597 | Eli Lilly and Company | Healthy | April 3, 2023 | Phase 1 | NCT04847557 | Eli Lilly and Company | Obesity|Heart Failure With Preserved Ejection Fraction | April 20, 2021 | Phase 3 | NCT05978713 | Eli Lilly and Company | Healthy | July 31, 2023 | Phase 1 | NCT03987919 | Eli Lilly and Company | Type 2 Diabetes | July 30, 2019 | Phase 3 | NCT03951753 | Eli Lilly and Company | Diabetes Mellitus, Type 2 | June 28, 2019 | Phase 1 | NCT05696847 | Eli Lilly and Company | Obesity | February 7, 2023 | Phase 1 | NCT05912621 | Stanford University|Eli Lilly and Company | Obesity|Overweight and Obesity|Overweight | June 2023 | Phase 2 | NCT04255433 | Eli Lilly and Company | Type 2 Diabetes Mellitus | May 29, 2020 | Phase 3 | NCT04311411 | Eli Lilly and Company | Obesity|Overweight | August 24, 2020 | Phase 1 | NCT04660643 | Eli Lilly and Company | Obesity|Overweight | March 29, 2021 | Phase 3 | NCT05582096 | Eli Lilly and Company | Overweight|Obesity | November 11, 2022 | Phase 1 | NCT05556512 | Eli Lilly and Company | Obesity|Overweight | October 11, 2022 | Phase 3 | NCT04050553 | Eli Lilly and Company | Diabetes Mellitus, Type 2|Hypoglycemia | February 24, 2020 | Phase 1 | NCT05433584 | Eli Lilly and Company | Type 2 Diabetes | August 1, 2022 | Phase 4 | NCT04050670 | Eli Lilly and Company | Healthy | September 13, 2019 | Phase 1 | NCT04311424 | Eli Lilly and Company | Healthy | July 28, 2020 | Phase 1 | NCT04657003 | Eli Lilly and Company | Type 2 Diabetes|Overweight|Obesity | March 29, 2021 | Phase 3 | NCT02759107 | Eli Lilly and Company | Healthy|Type 2 Diabetes Mellitus (T2DM) | May 11, 2016 | Phase 1 | NCT05706506 | Eli Lilly and Company | Type 2 Diabetes|Diabetes Mellitus, Type 2 | March 8, 2023 | Phase 4 | NCT04081337 | Eli Lilly and Company | Obesity | July 9, 2020 | Phase 1 | NCT04235959 | Eli Lilly and Company | Diabetes Mellitus, Type 2 | October 21, 2020 | Phase 1 | NCT05766358 | Pennington Biomedical Research Center | Weight Loss|Weight Gain|Obesity | October 6, 2022 | | NCT03861039 | Eli Lilly and Company | Type 2 Diabetes Mellitus | March 30, 2019 | Phase 3 | NCT05024032 | Eli Lilly and Company | Obesity|Overweight|Metabolism and Nutrition Disorder | September 1, 2021 | Phase 3 | NCT05691712 | Eli Lilly and Company | Diabetes Type 2|Diabetes Mellitus|Glucose Metabolism Disorders|Metabolic Disease|Endocrine System Diseases | February 5, 2023 | Phase 3 | NCT05659368 | Ospedale San Raffaele | Wolfram Syndrome | January 2023 | Phase 2 | NCT03131687 | Eli Lilly and Company | Type 2 Diabetes Mellitus | May 24, 2017 | Phase 2 |
|
---|